ArticleCancer discovery2021
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 5 pooled it
11.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
205 citing papers in PubMed, 5 syntheses or guidelines pooled it, 251 citations in OpenAlex.
- Avoidance of cardiac toxicity during the application of immune checkpoint inhibitors: a safety systematic review combining network meta-analysis and pharmacovigilance study.Frontiers in immunology · 2026Pooled it
- Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis.Journal of translational medicine · 2025Pooled it
- Effect of immune checkpoint inhibitor therapy on biventricular mechanics in cancer patients over a short-term follow-up: a systematic review.Frontiers in immunology · 2025Pooled it
- Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports.Frontiers in immunology · 2023Pooled it
- Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.Frontiers in medicine · 2022Pooled it
- Mapping the global landscape of research on immune checkpoint inhibitor-associated cardiotoxicity: A quantitative and visualized bibliometric study (2016-2025).Human vaccines & immunotherapeutics · 2026Article
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Heart-specific T cell responses: from antigens to disease mechanisms.Nature reviews. Cardiology · 2026Review
- Review
- Abatacept for steroid-refractory fulminant immune checkpoint inhibitor myocarditis with triple M overlap syndrome: a case report with serial endomyocardial biopsy assessment.European heart journal. Case reports · 2026Article
- A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management.Journal of thoracic disease · 2026Review
- Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis.Science advances · 2026Article
- PD-1/PD-L1 Signaling in Non-ICI Myocarditis.JACC. Basic to translational science · 2026Article
- PD-1/PD-L1 inhibitor induces systemic inflammation and alters cardiac lipid metabolism in C57BL/6 J mice.Human cell · 2026Article
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- Microbiota and immune-related adverse events in cancer immunotherapy.Nature reviews. Cancer · 2026Review
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
- Inhibition of the programmed death protein 1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischaemia.Cardiovascular research · 2026Article
- Review
145 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 7 institutions in 3 countries.
Spencer C Wei *Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jallison@mdanderson.org spencer.wei@gmail.com javid.moslehi@vumc.org.ORCID 0000-0001-9673-9683
Wouter C Meijers *Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Margaret L AxelrodDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-4713-8798
Nana-Ama A S AnangDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8495-2978
Elles M ScreeverDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Elizabeth C WescottDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-3340-213X
Douglas B JohnsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Elizabeth WhitleyDepartment of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lorenz LehmannDepartment of Cardiology, University Hospital of Heidelberg, Heidelberg, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, German Research Center (DKFZ), Heidelberg, Germany.
Pierre-Yves CourandHospices Civils de Lyon, Service de cardiologie, IMMUCARE, Hôpital de la Croix-Rousse et Hôpital Lyon Sud, Lyon, France; Université de Lyon, CREATIS UMR INSERM U1044, INSA, Lyon France.
James J MancusoDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lauren E HimmelDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0628-9998
Benedicte Lebrun-VignesDepartment of Pharmacology, APHP. Sorbonne Université, INSERM, CIC-1901, UNICO-GRECO Cardiooncology Program, Paris, France.
Matthew J WleklinskiDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Bjorn C KnollmannDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Jayashree SrinivasanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas.ORCID 0000-0001-9478-7518
Yu LiDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas.
Oluwatomisin T AtolagbeDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xiayu RaoDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yang ZhaoDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lauren I R EhrlichDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas.
Padmanee SharmaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Joe-Elie SalemDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0331-3307
Justin M BalkoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-4263-5974
Javid J Moslehi *Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. jallison@mdanderson.org spencer.wei@gmail.com javid.moslehi@vumc.org.
James P Allison *Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jallison@mdanderson.org spencer.wei@gmail.com javid.moslehi@vumc.org.ORCID 0000-0001-8980-5697
The University of Texas MD Anderson Cancer Center · USVanderbilt University Medical Center · USInserm · FRThe University of Texas at Austin · USGerman Cancer Research Center · DELivestrong Foundation · USUniversité Claude Bernard Lyon 1 · FR
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MCLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4MToward a Mechanism-Based Approach to Treating Cardiac ArrhythmiaR35HL144980 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KNOLLMANN, BJORN C · 2019 to 2025
$7.1MVanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3MMedical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8MNovel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3MLong-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3M(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibitionR01CA227481 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BALKO, JUSTIN M, JOHNSON, DOUGLAS B · 2019 to 2023
$2.6MNovel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR56HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2018 to 2018
$613kNCI NIH HHS F30 CA236157NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA227481NHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R35 HL144980NHLBI NIH HHS R56 HL141466NIDDK NIH HHS U24 DK059637NIDDK NIH HHS U2C DK059637NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM007569NIGMS NIH HHS T32 GM152284NIH HHS S10 OD023475
Abstract
Immune checkpoint inhibitors (ICI) targeting CTLA4 or PD-1/PD-L1 have transformed cancer therapy but are associated with immune-related adverse events, including myocarditis. Here, we report a robust preclinical mouse model of ICI-associated myocarditis in which monoallelic loss of
Indexed as
AnimalsBiomarkers, TumorCardiotoxicityDisease ManagementDisease Models, AnimalDisease SusceptibilityElectrocardiographyHumansImmune Checkpoint InhibitorsMiceMolecular Targeted TherapyMyocarditisNeoplasmsBiomarkers, TumorImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.